Claims:

1. Use of *N*-{(*R*)-1-[8-chloro-2-(1-oxypyridin-3-yl)quinolin-3-yl]-2,2,2-trifluoroethyl}pyrido[3,2-*d*]pyrimidin-4-ylamine, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment and/or prevention of Sjögren's syndrome.

2. The use according to claim 1, wherein the Sjögren's syndrome is primary Sjögren's syndrome.